BDTX Black Diamond Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

   CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.
   

   A webcast of the presentation can be accessed by visiting the investor relations section of the Company's website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived on the site for 90 days.

   About …

   View Full Article
2. 12 May 2022 Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

   - Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine -

   CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the publication of data identifying new oncogenic HER2 allosteric mutations that support the Mutation-Allostery-Pharmacology (MAP) discovery engine's capabilities and further suggest the need for novel inhibitors to treat HER2-mutant cancers. The paper, titled "Computational and Functional Analyses of HER2 Mutations Revealing Allosteric Activation Mechanisms and Altered…

   View Full Article
3. 11 May 2022 Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

   • Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous system (CNS) tumors; clinical update expected in 2023
     
   • Continued strategic focus on development of BDTX-1535, BDTX-4933 and MAP drug discovery engine enabled small molecule drug discovery efforts
   • Financial position strengthened and cash runway extended into third quarter of 2024; cash, cash equivalents, and investments of approximately $179.7 million as of March 31, 2022

   CAMBRIDGE, Mass. and NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey…

   View Full Article
4. 25 April 2022 Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

    – Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts –

    – Company to discontinue development of BDTX-189 and reduce workforce to extend its cash runway into 3Q 2024, supporting execution of key milestones –

   CAMBRIDGE, Mass. and NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones.

   …

   View Full Article
5. 18 April 2022 Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

   - Clinical update expected in second half of 2023 -

   CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the dosing of the first patient in the Phase 1 study evaluating BDTX-1535, a MasterKey inhibitor of epidermal growth factor receptor (EGFR) for the treatment of both non-small cell lung cancer (NSCLC) and glioblastoma (GBM)derived from Black Diamond's MAP discovery engine.

   "The dosing of the first patient in our Phase 1 study of BDTX-1535, a next generation brain-penetrant inhibitor of oncogenic EGFR MasterKey mutations is an important step as we believe this…

   View Full Article